Jaguar Animal Health Inc Cash Flow Conversion Efficiency
Jaguar Animal Health Inc cash flow conversion efficiency. Based on the latest financial reports, Jaguar Animal Health Inc (JAGX) has a cash flow conversion efficiency ratio of -1.085x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.34 Million) by net assets ($4.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Jaguar Animal Health Inc (2007–2025)
Cash flow conversion efficiency of Jaguar Animal Health Inc from 2007 to 2025. This chart illustrates how Jaguar Animal Health Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View JAGX stock price for real-time trading data and today's change.
Jaguar Animal Health Inc Cash Flow Conversion Ratio Explained
Jaguar Animal Health Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Jaguar Animal Health Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jaguar Animal Health Inc ranked by their cash flow conversion efficiency. Also see JAGX stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shree Ram Proteins Limited
NSE:SRPL
|
0.086x |
|
LABOCANNA S.A. ZY-10
F:9Y2
|
-0.139x |
|
Tessin Nordic Holding AB
ST:TESSIN
|
0.101x |
|
Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
XETRA:EFF
|
0.000x |
|
Europejskie Centrum Odszkodowań SA
WAR:EUC
|
0.002x |
|
Universe Pharmaceuticals Inc
NASDAQ:UPC
|
-0.136x |
|
Strix Group Plc
LSE:KETL
|
0.023x |
|
Speedy Hire PLC
LSE:SDY
|
0.278x |
Annual Cash Flow Conversion Efficiency for Jaguar Animal Health Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Jaguar Animal Health Inc from 2007 to 2025. Review Jaguar Animal Health Inc (JAGX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-18.69 Million | $5.80 Million | -0.310x | +93.14% |
| 2024-12-31 | $6.49 Million | $-29.38 Million | -4.525x | +33.34% |
| 2023-12-31 | $4.90 Million | $-33.24 Million | -6.788x | -127.81% |
| 2022-12-31 | $-1.36 Million | $-33.10 Million | 24.413x | +927.47% |
| 2021-12-31 | $11.85 Million | $-34.97 Million | -2.950x | -232.18% |
| 2020-12-31 | $17.20 Million | $-15.28 Million | -0.888x | +53.66% |
| 2019-12-31 | $10.67 Million | $-20.46 Million | -1.917x | +54.61% |
| 2018-12-31 | $5.38 Million | $-22.73 Million | -4.223x | -641.85% |
| 2017-12-31 | $17.26 Million | $-9.82 Million | -0.569x | -109.69% |
| 2016-12-31 | $-2.45 Million | $-14.41 Million | 5.873x | +280.47% |
| 2015-12-31 | $4.40 Million | $-14.32 Million | -3.254x | +34.70% |
| 2014-12-31 | $1.10 Million | $-5.46 Million | -4.984x | -46.54% |
| 2007-12-31 | $5.40 Million | $-18.37 Million | -3.401x | -- |
About Jaguar Animal Health Inc
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. I… Read more